News

Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations. The answer may surprise investors who have been watching Merck's blockbuster momentum.

Amgen’s updated analyst model now points to a fair value price target of US$388.03, compared with the prior US$371.93. This provides a slightly higher anchor for how the stock is being valued today. This shift comes as recent research highlights a split view, with some analysts focusing on strong commercial execution and others stressing that questions around patents and the pipeline may already be reflected in the share price. As you read on, you will see how to interpret these moving...

In the most recent trading session, Amgen (AMGN) closed at $385.65, indicating a +1.55% shift from the previous trading day.

Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.

AMD, Linde and Amgen highlight AI demand, contracted growth and drug launches, while supply, margin and pipeline risks remain key factors.

On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes. Analysts said Amgen’s olpasiran faces […]

Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.

Key Stats for Amgen StockCurrent Price: $375. 65Target Price (Mid): ~$495Street Target: ~$388Potential Total Return: ~32%Annualized IRR: ~6.

Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.

The pharmaceutical giant's track record in past bear markets is fairly impressive.

Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.

The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.

Amgen (NASDAQ:AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns. Dittrich, who previou

ADM, COCO, AMGN and CNC offer defensive exposure as inflation, oil prices and weak consumer sentiment fuel market volatility.

Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.

Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.

Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. And since Amgen’s […]

During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]

Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.

Amgen (NASDAQ:AMGN) executives highlighted growth across its key commercial products, progress in late-stage development programs and a continued focus on profitability and cash returns during a Wells Fargo biotech and pharma discussion. Chief Financial Officer Thomas Dittrich, who recently returne

AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.

Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.

One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (NYSE:AZN) received a positive boost after their combination of Amgen’s Imdelltra and AstraZeneca’s Imfinzi significantly improved overall survival in a late-stage trial involving patients with extensive-stage small-cell lung cancer. The combination was tested as a maintenance treatment against Imfinzi alone in patients whose disease had not progressed after initial […]

Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.

The latest trading day saw Amgen (AMGN) settling at $382.47, representing a -2.25% change from its previous close.

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.